SCHEMBL30385495

SCHEMBL30385495

CCc1cc(Nc2nccn3c(-c4ccc(OC)c(F)c4F)cnc23)ccc1C(=O)NC1CCC(NC(=O)OC(C)(C)C)CC1

nearest known ligand 0.43

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ TTK P33981 15/20 0.43
▸ AXL P30530 4/20 0.39
▸ AAK1 Q2M2I8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22123681 0.96 TTK (0.39) TTKAXLAAK1
SCHEMBL30385306 0.92 TTK (0.49) TTKAXL
SCHEMBL24112106 0.91 TTK (0.44) TTKAXL
SCHEMBL22139189 0.91 TTK (0.43) TTKAXL
SCHEMBL22139188 0.90 TTK (0.43) TTKAXL
SCHEMBL22123713 0.90 TTK (0.43) TTKAXL
SCHEMBL24940098 0.90 TTK (0.43) TTKAXL
SCHEMBL30403448 0.90 TTK (0.39) TTKAXL
SCHEMBL25445368 0.89 TTK (0.42) TTKAXL
SCHEMBL22139190 0.89 TTK (0.45) TTKAXL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4161931-B1 NOVEL IMIDAZOPYRAZINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2026-02-18 — — EP disclosed
US-20230141600-A1 IMIDAZOPYRAZINE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2023-05-11 — — US disclosed
EP-4161931-A1 NOVEL IMIDAZOPYRAZINE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2023-04-12 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230141600-A1 IMIDAZOPYRAZINE DERIVATIVES IKZF3, RRP15, IK TTK 4336/4885AXL 1164/4885AAK1 3378/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback